BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Key Stats

• Today's Range: $288.36 to $294.30
• 50-Day Range: $274.73 to $323.87
• 52-Week Range: $239.25 to $385.22
• Volume: 98,618 shs
• Average Volume: 251,505 shs
• Market Capitalization: $31.84 billion
• P/E Ratio: 64.94
• Dividend Yield: N/A
• Price Target: $389.15
• Consensus Rating: Moderate Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 86% of companies evaluated by MarketBeat, and ranked 100th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 11 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

BeOne Medicines has a consensus price target of $389.15, representing about 34.1% upside from its current price of $290.16.

Amount of Analyst Coverage

BeOne Medicines has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 83.54%

Earnings Growth

Earnings for BeOne Medicines are expected to grow by 83.54% in the coming year, from $5.65 to $10.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is 64.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is 64.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.27.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.02% of the float of BeOne Medicines has been sold short.

Short Interest Ratio / Days to Cover

BeOne Medicines has a short interest ratio ("days to cover") of 4.15.

Change versus previous month

Short interest in BeOne Medicines has recently decreased by 5.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.23

News Sentiment

BeOne Medicines has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for BeOne Medicines this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $505,791.00 in company stock.

Percentage Held by Insiders

6.19% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/01/2026
• Today: 5/29/2026
• Study update: 6/01/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: N/A
• Phone: 13459494123
• Fax: N/A
• Employees: 12,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BeOne Medicines: $389.15
• High Price Target: $425.00
• Low Price Target: $290.00
• Potential Upside/Downside: +34.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.47
• Trailing P/E Ratio: 64.83
• Forward P/E Ratio: 51.32
• P/E Growth: N/A
• Net Income: $286.93 million
• Net Margins: 8.94%
• Pretax Margin: 11.42%
• Return on Equity: 12.06%
• Return on Assets: 6.69%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.64
• Quick Ratio: 3.27

Sales & Book Value

• Annual Sales: $5.34 billion
• Price / Sales: 5.95
• Cash Flow: $3.78 per share
• Price / Cash Flow: 76.76
• Book Value: $43.39 per share
• Price / Book: 6.68

Miscellaneous

• Outstanding Shares: 109,720,000
• Free Float: 102,928,000
• Market Cap: $31.81 billion
• Optionable: N/A
• Beta: 0.50